Research programme: farnesyl transferase inhibitors - Schering-Plough

Drug Profile

Research programme: farnesyl transferase inhibitors - Schering-Plough

Alternative Names: Sch 704742

Latest Information Update: 24 Aug 2009

Price : $50

At a glance

  • Originator Schering-Plough
  • Class Pyridines
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Aug 2009 Discontinued - Preclinical for Cancer in USA (PO)
  • 03 Oct 2006 This programme is still in active development
  • 03 Oct 2006 Preclinical data presented at the 232nd American Chemical Society National Meeting (232nd-ACS-2006) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top